Endocrinology and Endocannabinology: The integration of systems that regulate lifelong health

The connection between endocrinology and endocannabinology runs deep, and both converge on the same physiological principle: maintaining homeostasis.

The difference is that endocrinology traditionally views this regulation through hormones and their axes, while endocannabinology adds a modulatory network—the endocannabinoid system (ECS)—capable of fine-tuning neuronal, hormonal, metabolic, immunological, and behavioral activity.

A review published in 2026 neatly summarizes this idea: the ECS should not be viewed as a “new endocrine axis,” but as a dynamic regulatory network that modulates the translation of neural activity into hormonal responses [1,2].

This perspective helps explain why the endocannabinoid system sparks so much interest within endocrinology.

Unlike a classic hormonal axis, which is organized in a relatively defined sequence of signals and responses, the ECS functions as a modulatory network: it receives information about the body's physiological state and modulates the intensity and timing of different cellular and neuroendocrine responses.

It is precisely this characteristic that brings endocannabinology closer to a more integrated view of human physiology. (1;2)

The hypothalamus as a meeting point

The hypothalamus is where one of the major meeting points between these systems occurs.

The hypothalamus integrates information regarding energy status, sleep, circadian rhythms, temperature, stress, reproduction, and nutrient availability, and from this, coordinates much of the neuroendocrine response.

In this sense, the hypothalamus can be understood as a true interface between the environment, behavior, and physiology.

It not only receives information about the body's internal state, but also integrates metabolic, neural, and hormonal signals and translates them into responses involving feeding, stress, reproduction, fluid and electrolyte balance, and endocrine function.

The presence and activity of ECS components in this region help explain why its signaling can influence so many seemingly distinct processes that are, within the body, deeply interconnected [2].

Intense endocannabinoid signaling occurs within this very territory.

The endocannabinoids anandamide (AEA) and 2-AG, acting primarily through CB1, frequently function as retrograde messengers, modulating the release of GABA and glutamate and, consequently, the activity of hypothalamic neurosecretory neurons.

This retrograde communication is one of the most intriguing features of the ECS.

Rather than functioning merely as a one-way transmission pathway, endocannabinoid signaling allows the postsynaptic cell to influence the activity of the presynaptic terminal, acting as a fine-tuning mechanism for neuronal transmission.

In the neuroendocrine context, this ability to modulate neurotransmitter release helps explain how the ECS can act on circuits simultaneously involved in stress, feeding, reproduction, and homeostasis [2,3].

Thus, we can see that environment/lifestyle activates the CNS/hypothalamus and the ECS, as both modulate neuroendocrine axes, metabolism, behavior, and homeostasis.

The ECS interacts, with varying degrees of evidence, across the HPA axis (CRH–ACTH–cortisol), HPG axis (GnRH–LH/FSH–sex steroids), thyroid axis, GH/IGF-1 axis, prolactin, oxytocin, and vasopressin.

The endocannabinoid system and the stress axis

A particularly important example is that of stress and cortisol.

This is perhaps the best-demonstrated connection.

The ECS participates in the control of the hypothalamic-pituitary-adrenal (HPA) axis and the recovery of homeostasis following a physical or psychological threat.

Glucocorticoids, in turn, can rapidly recruit endocannabinoid signaling in the hypothalamus, creating a feedback mechanism on CRH-producing neurons.

This relationship is particularly interesting because it demonstrates that the ECS does not simply act “against” or “in favor of” stress.

Its function is more sophisticated: depending on the circuit, timing, and physiological context, endocannabinoid signaling can modulate the intensity of the response to the stressor and participate in returning the body to its baseline state.

Experimental studies even indicate that glucocorticoids can mobilize 2-AG, reinforcing the existence of bidirectional communication between the HPA axis and the endocannabinoid system [3,9].

This creates a remarkably interesting interface among endocrinology, chronic stress, sleep, mental health, and metabolism.

Conceptually speaking:

Stressor activates the HPA axis, which stimulates cortisol release and endocannabinoid signaling, modulating the stress circuit and the recovery of homeostasis.

When this balance becomes chronically dysfunctional, issues traditionally addressed by endocrinology begin to overlap: sleep disturbances, visceral obesity, insulin resistance, altered appetite and eating behavior, reproductive dysfunction, and increased cardiometabolic risk.

The endocannabinoid system and metabolism

Metabolism is probably the second major intersection between endocrine systems and the ECS, as the latter is not restricted to the brain.

ECS components are present in adipose tissue, the liver, the gastrointestinal tract, muscle, and other metabolically active tissues.

This peripheral distribution is fundamental to understanding the ECS as a physiological network rather than merely a brain system.

Its components are present in various metabolically active tissues and participate in communication between energy availability, nutrient storage, and substrate utilization.

In adipose tissue, for example, endocannabinoid signaling is linked to the regulation of lipid metabolism and communication with other hormonal signals involved in energy balance [4, 6, 10].

It plays a role, for instance, in regulating appetite and food reward, fat storage, lipogenesis, glucose and lipid metabolism, insulin sensitivity, and metabolic inflammation.

In obesity, particularly visceral obesity, there is evidence of hyperactivity of certain ECS components, including elevated AEA/2-AG levels in specific compartments and increased CB1 signaling [6,7,10,12].

The significance of this observation lies less in attributing obesity to the ECS as an isolated cause and more in recognizing that it participates in a much broader metabolic network.

Leptin, insulin, ghrelin, adipose tissue-derived signals, and nutritional cues converge on circuits that regulate food intake, energy expenditure, and energy storage.

In experimental models and metabolic studies, alterations in endocannabinoid signaling have been associated with changes in insulin sensitivity, lipid metabolism, and adipose tissue function [4,6,7,10].

All of this builds a particularly compelling bridge: endocrinology, obesity, diabetes, insulin resistance, and metabolic syndrome.

Within endocannabinology, there is modulation of the ECS involved in food intake, energy storage, inflammation, and metabolism, alongside the interaction of the ECS with systems well known to endocrinologists, such as leptin, ghrelin, insulin, the gut-brain axis, and circadian rhythms [4,7,10].

Reproduction and sex hormones

In reproduction and sex hormones, the relationship is bidirectional, as it is not merely a matter of “cannabinoids interfering with hormones.”

ECS components are distributed throughout the hypothalamic-pituitary-gonadal axis and within the gonads themselves.

At the same time, estradiol, progesterone, and androgens can modulate endocannabinoid signaling.

This bidirectionality is particularly relevant because it places the ECS within a physiological dialogue already familiar to endocrinology: hormones not only exert effects on their target tissues, but also participate in regulating signaling systems that modulate the body's own responsiveness.

Experimental and observational studies demonstrate relationships between endocannabinoids, gonadotropins, and sex steroids, including fluctuations in anandamide throughout the reproductive cycle [5,11].

This opens a promising area of interest for research into fertility, sexual function, gonadal health, menopause, and reproductive aging, although it is crucial to distinguish physiological plausibility from established therapeutic indications.

Prevention, quality of life, and longevity

And where do prevention, quality of life, and longevity fit into this integration?

This is precisely the most intriguing idea, yet it is essential to distinguish between a highly promising conceptual model and what currently has sufficient clinical evidence to warrant specific interventions [8].

A large proportion of chronic diseases associated with aging involves a progressive loss of the ability to maintain homeostasis: visceral obesity, insulin resistance, chronic low-grade inflammation, sleep disturbances, chronic stress, muscle loss, hormonal changes, and neurodegeneration.

Preventive endocrinology acts directly upon several of these determinants.

The ECS, in turn, participates in regulating these very systems [4,6,10].

This is where the concept of lifelong health gains relevance.

Talking about healthy aging does not simply mean increasing the number of years lived, but preserving functional capacity, metabolic health, cognitive function, autonomy, and quality of life for as long as possible.

Interest in the ECS in this context arises precisely from its involvement in processes spanning these domains, such as metabolism, inflammation, stress response, sleep, and neural function.

However, the fact that the ECS participates in these processes does not, in itself, mean that its pharmacological modulation has been proven to extend human lifespan.

This distinction between biological mechanism, therapeutic hypothesis, and clinical evidence is fundamental [8,12,13].

Neuroendocrine and endocannabinoid integration

Figure 1 — Neuroendocrine and endocannabinoid integration in maintaining homeostasis

From physiological regulation to lifelong health.

Figure 1. Integration among behavioral and metabolic factors, the central nervous system/hypothalamus, the endocannabinoid system (ECS), and neuroendocrine and immune/metabolic systems, converging to maintain homeostasis and preserve functional health throughout life.

This is a more scientifically defensible way to discuss longevity.

Today, we lack sufficient clinical evidence to state that CBD, THC, or any other phytocannabinoid extends human longevity.

A systematic review published in 2025 on cannabis, aging, and longevity identified biologically interesting signals, but emphasized that major gaps remain and that evidence is still insufficient for such conclusions [8].

There is also growing interest in the ECS regarding brain aging, neuroinflammation, and neurodegeneration, yet once again, much of the mechanistic and therapeutic evidence remains in the preclinical stage [8].

This may be one of the most critical points for the future of endocannabinology: translating biologically plausible hypotheses into well-formulated clinical questions.

Preventive endocannabinology

Research on aging and the ECS does not need to start from the promise of a “longevity therapy,” but from more precise questions:

Which pathways remain functional throughout aging?

Which become dysfunctional?

In what contexts could modulating these pathways enhance function, recovery, or quality of life?

And, most importantly, which of these effects can be consistently demonstrated in humans?

This leads to an important paradigm shift.

The broader concept of preventive endocannabinology is not simply about “prescribing cannabis to prevent diseases.”

The best framework might be defined as:

“The integration of endocrinology and endocannabinology seeks to understand and modulate the neuroendocrine, metabolic, and endocannabinoid mechanisms responsible for maintaining homeostasis, aiming to reduce risk factors, improve metabolic and functional health, and foster quality of life and healthy aging.

In this model, exercise, sleep, nutrition, body composition, stress reduction, circadian rhythms, and metabolic health remain the cornerstones.

Pharmacological modulation of the ECS, including phytocannabinoids when clinically indicated, would serve as a complementary tool rather than the foundation of the longevity strategy.”

Endocrinology and endocannabinology: an integrated view

In a single sentence, I would summarize the convergence of these two fields as follows:

“Endocrinology studies the major hormonal systems that maintain homeostasis; endocannabinology adds a modulatory network that helps coordinate the body's response to the environment, stress, and metabolic demands.

The integration of both offers a promising field for medicine focused not only on disease treatment, but on the preservation of metabolic health, functional capacity, and quality of life.”

This concept even has the potential to serve as the scientific foundation for a professional positioning or a program in “Endocrinology, Endocannabinoid System, and Longevity,” provided longevity is framed as quality of life/healthy aging, rather than an ungrounded promise of cannabinoid-induced life extension.

References

1. NAGYOVA, Anabela; HLAVACOVA, Natasa. Endocannabinoid signalling in the regulation of hypothalamic-pituitary neuroendocrine circuits: A review. Endocrine Regulations, v. 60, n. 1, p. 98-110, 2026.
2. TASKER, Jeffrey G. et al. Endocannabinoid regulation of neuroendocrine systems. International Review of Neurobiology, v. 125, p. 163-201, 2015. DOI: 10.1016/bs.irn.2015.09.003. Epub 2015 Nov 11. PMID: 26638767.
3. HILLARD, Cecilia J.; BEATKA, Margaret; SARVAIDEO, Jenna. Endocannabinoid signaling and the hypothalamic-pituitary-adrenal axis. Comprehensive Physiology, v. 7, n. 1, p. 1-15, 2017. DOI: 10.1002/cphy.c160005.
4. PAGOTTO, Uberto et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews, v. 27, n. 1, p. 73-100, 2006.
5. GORZALKA, Boris B.; DANG, Silvain S. Minireview: Endocannabinoids and gonadal hormones: bidirectional interactions in physiology and behavior. Endocrinology, v. 153, n. 3, p. 1016-1024, 2012. DOI: 10.1210/en.2011-1643. Epub 2011 Dec 30. PMID: 22210740.
6. VAN EENIGE, R.; VAN DER STELT, M.; RENSEN, PCN.; KOOIJMAN, S. Regulation of adipose tissue metabolism by the endocannabinoid system. Trends in Endocrinology & Metabolism, v. 29, n. 5, p. 326-337, 2018. DOI: 10.1016/j.tem.2018.03.001. Epub 2018 Mar 24. PMID: 29588112.
7. AKURATI, S.; HANLON, EC. Beyond the Scale: Exploring the Endocannabinoid System's Impact on Obesity. Current Diabetes Reports, v. 25, n. 1, p. 6, 2025. DOI: 10.1007/s11892-024-01562-2. Epub 2024 Nov 15. PMID: 39543055.
8. NAIN, S.; SINGH, N.; SCHLAG, AK. et al. The impact of cannabis use on ageing and longevity: a systematic review of research insights. Journal of Cannabis Research, v. 7, n. 1, p. 52, 2025. DOI: 10.1186/s42238-025-00267-x.
9. HILL, Matthew N.; TASKER, Jeffrey G. Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience, v. 204, p. 5-16, 2012. DOI: 10.1016/j.neuroscience.2011.12.030. Epub 2011 Dec 24. PMID: 22214537; PMCID: PMC3288468.
10. GATTA-CHERIFI, B.; COTA, D. New insights on the role of the endocannabinoid system in the regulation of energy balance. International Journal of Obesity, v. 40, n. 2, p. 210-219, 2016. DOI: 10.1038/ijo.2015.179. Epub 2015 Sep 16. PMID: 26374449.
11. EL-TALATINI, MR.; TAYLOR, AH.; KONJE, JC. The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle. Fertility and Sterility, v. 93, n. 6, p. 1989-1996, 2010. DOI: 10.1016/j.fertnstert.2008.12.033. Epub 2009 Feb 6. PMID: 19200965.
12. RUIZ DE AZUA, I. et al. Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages. Journal of Clinical Investigation, v. 127, n. 11, p. 4148-4162, 2017. DOI: 10.1172/JCI83626. Epub 2017 Oct 16. PMID: 29035280; PMCID: PMC5663356.